Patents matching “formulation”

US 8541025

Co-crystals and pharmaceutical formulations comprising the same

Vertex Pharmaceuticals Incorporated · Granted Sep 24, 2013 · Expires Sep 19, 2033

US 8513198

Pharmaceutical formulation for reducing pain

Jazz Pharmaceuticals International III Limited · Granted Aug 20, 2013 · Expires Aug 15, 2033

US 8507012

Formulations comprising extracts from primitive plant species (mosses, ferns and lichens) to treat and prevent cancers

Southern Connecticut State University · Granted Aug 13, 2013 · Expires Aug 8, 2033

US 8491880

Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates

Mersana Therapeutics, Inc. · Granted Jul 23, 2013 · Expires Jul 18, 2033

US 8481046

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Jul 9, 2013 · Expires Jul 4, 2033

US 8470364

Once daily formulations of tetracyclines

Supernus Pharmaceuticals, Inc. · Granted Jun 25, 2013 · Expires Jun 20, 2033

US 8460643

Formulation for prophylaxis of oral cavity diseases

OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU “WELDUP” · Granted Jun 11, 2013 · Expires Jun 6, 2033

US 8449909

Abuse-deterrent drug formulations

Collegium Pharmaceutical, Inc. · Granted May 28, 2013 · Expires May 23, 2033

US 8435943

Protein stabilization formulations

Advanced Technologies and Regenerative Medicine, LLC · Granted May 7, 2013 · Expires May 2, 2033

US 8435570

Nitrite formulations and their use as nitric oxide prodrugs

The Board of Regents of the University of Texas System · Granted May 7, 2013 · Expires May 2, 2033

US 8431116

Norovirus vaccine formulations

Takeda Vaccines (Montana), Inc. · Granted Apr 30, 2013 · Expires Apr 25, 2033

US 8404638

Dimer VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Mar 26, 2013 · Expires Mar 21, 2033

US 8394405

Once daily formulations of tetracyclines

Supernus Pharmaceuticals, Inc. · Granted Mar 12, 2013 · Expires Mar 7, 2033

US 8394406

Once daily formulations of tetracyclines

Supernus Pharmaceuticals, Inc. · Granted Mar 12, 2013 · Expires Mar 7, 2033

US 8372877

Stabilized statin formulations

Cumberland Pharmaceuticals Inc. · Granted Feb 12, 2013 · Expires Feb 7, 2033

US 8372979

Process for the production of high-purity 2,4′-dimethyl-3-piperidino-propiophenone (tolperisone), pharmaceutical compositions that contain the latter, as well as active ingredient formulations that contain tolperisone

SANOCHEMIA PHARMAZEUTIKA AG · Granted Feb 12, 2013 · Expires Feb 7, 2033

US 8372800

Albumin-free factor VIII formulations

UNIVERSITY OF CONNECTICUT · Granted Feb 12, 2013 · Expires Feb 7, 2033

US 8367638

Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

GALECTIN THERAPEUTICS, INC. · Granted Feb 5, 2013 · Expires Jan 31, 2033

US 8367734

Stable epinephrine suspension formulation with high inhalation delivery efficiency

Amphastar Pharmaceuticals, Inc. · Granted Feb 5, 2013 · Expires Jan 31, 2033

US 8357676

Ansamycin formulations and methods of use thereof

Infinity Discovery, Inc. · Granted Jan 22, 2013 · Expires Jan 17, 2033

US 8349987

Adhesive formulations

Covidien LP · Granted Jan 8, 2013 · Expires Jan 3, 2033

US 8350079

Treprostinil formulation

United Therapeutics Corporation · Granted Jan 8, 2013 · Expires Jan 3, 2033

US 8349355

Formulations of lipoic acid and hyaluroinc acid and/or the derivatives thereof in the pharmaceutical and cosmetic fields

Anika Therapeutics S.r.l. · Granted Jan 8, 2013 · Expires Jan 3, 2033

US 8349892

Solid formulations of prostacyclin analogs

United Therapeutics Corporation · Granted Jan 8, 2013 · Expires Jan 3, 2033